TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
P/B ratio for TScan Therapeutics, Inc. (TCRX)
P/B ratio as of 2023: 2.53
According to TScan Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.53. At the end of 2022 the company had a P/B ratio of 0.37.
P/B ratio history for TScan Therapeutics, Inc. from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 2.53 |
| 2022 | 0.37 |
| 2021 | 0.67 |
| 2020 | -6.17 |
| 2019 | -15.28 |